<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02542865</url>
  </required_header>
  <id_info>
    <org_study_id>204477</org_study_id>
    <nct_id>NCT02542865</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Impact of Fortified Malt Based on Immunity Outcomes in School Children</brief_title>
  <official_title>Clinical Study to Measure the Impact of Fortified Malt Based Food on Immunity Outcomes in School Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the hypothesis that a fortified malt based food may improve immunity
      outcomes in 7-10 year old school age children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a single centre, multiple sites, open label, two-arm, parallel-group, stratified
      by gender, matched pair cluster randomised, controlled study in children aged 7-10 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 24, 2017</start_date>
  <completion_date type="Anticipated">July 6, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 6, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of ill days</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>Number of ill days will be determined as number of days a participant is ill because of gastrointestinal (GI) and/orrespiratory illnesses as diagnosed by study physician.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of GI and respiratory illnesses</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>It will be determined as total number of illness episodes of GI and/or respiratory illnesses (each incidence of illness followed by at least 3 symptom free days) divided by duration of intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of GI illnesses</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>Severity of GI illnesses evaluated and classified as, diarrhea (Mild, increase of &lt;4 stools /day over baseline; Moderate, increase of 4 to 6 stools/day over baseline; Severe, increase of ≥7 loose stools/day over baseline) and vomiting (1-2 episodes [separated by 5 minutes] in 24 hours [hrs]; Moderate, 3-5 episodes (separated by 5 minutes) in 24 hrs; Severe, ≥6 episodes (separated by 5 minutes) in 24 hrs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of respiratory illnesses</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>Severity of respiratory illnesses evaluated and classified as, Mild or Grade1 (Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.), Moderate or Grade 2 (Minimal, local or non-invasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL). Instrumental ADL refer to school attendance, playing, studying, participating in school activities) and Severe or Grade 3 and 4 ([Grade 3] severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Self-care ADL refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden, [Grade 4] Life-threatening consequences; urgent indication indicated).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>School absenteeism assessment</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>Number of days will be determined when a child fails to attend school because of GI and/or respiratory illnesses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Body Mass Index (BMI)</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>BMI will be calculated using the formula: BMI= Weight [Kilogram (Kg)/ Height [meter (m)]^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in gut integrity/health as measured by Lactulose Mannitol test</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>Pre-measured amount of lactulose/mannitol solution [2 milliliter/Kilogram (mL/Kg) of body weight] containing lactulose [250 milligram/milliliter (mg/mL)] and mannitol (50 mg/mL) will be administered. All urine passed over duration of 2 ½ will be collected and analysed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in gut integrity/health as measured by Urinary Neopterin test</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>Spontaneous random urine will be collected from the participants and a volume of 2mL per participant will be stored and analysed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mucosal immunity</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>Mucosal immunity will be measured by quantitatively determining Salivary Immunoglobulin A (IgA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in nutrient biochemistry</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>Blood sample will be collected and serum levels of Vitamin A, B12, D (25-hydroxycholecalciferol), E, folate, of the trace elements selenium, zinc, copper, and iron will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ferritin, serum transferrin receptor, C-reactive protein and Alpha 1-acid glycoprotein levels</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>A total volume 7 mL of whole blood will be collected from each participant and serum levels of ferritin, serum transferrin receptor (sTfR), C-reactive protein (CRP), and Alpha 1-acid glycoprotein (AGP) will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Dietary Diversity Score</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>Dietary diversity score will be assessed through Individual Dietary Diversity, IDDS (a measure of the nutritional quality of the individual's diet). IDDS will be assessed based on the 'Guidelines for measuring household and individual dietary diversity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in macronutrients</measure>
    <time_frame>Baseline to 9 months</time_frame>
    <description>Intake of energy, protein, carbohydrate, and fat will be assessed from 24-hour dietary recall survey. A structured interview will be conducted based on a questionnaire. Parent/LARs (legally appropriate representative), will provide the majority of information, with the child making additions to fill in the gaps. Parents/LARs will recall all food and beverage consumed by the child during previous 24 hours and the information will be recorded. Calculation on energy and the macronutrients (protein, carbohydrates and fat) will be made using Dietsoft software.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">924</enrollment>
  <condition>Growth and Development</condition>
  <arm_group>
    <arm_group_label>Test Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fortified malt based food (27 grams) made up in 150 mL lukewarm water administered twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment was administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fortified malt based food</intervention_name>
    <description>Fortified malt based food</description>
    <arm_group_label>Test Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Demonstrates understanding of the study and willingness to participate as evidenced by
             the parent's and/or LAR's voluntary written informed consent as well as written assent
             by the child and has received a signed and dated copyof the informed consent form as
             well as the assent form.

          -  Boys and girls aged between 7-10 years

          -  Child and parent/LAR understand and are willing, able and likely to comply with all
             study procedures and restrictions.

          -  Good general and mental health with, in the opinion of the investigator or medically
             qualified designee: No clinically significant and relevant abnormalities in medical
             history or upon physical examination and absence of any condition that could affect
             the child's safety or wellbeing or their ability to understand and follow study
             procedures and requirements.

          -  Participants with HAZ of ≥-3 to ≤-1.

        Exclusion Criteria:

          -  Children in Care (CiC): A child who has been placed under the control or protection of
             an agency, organisation, institution or entity by the courts, the government or a
             government body, acting in accordance with powers conferred on them by law or
             regulation. The definition of a CiC can include a child cared for by foster parents or
             living in a care home or institution, provided that the arrangement falls within the
             definition above. The definition of a CiC does not include a child who is adopted or
             has an appointed legal guardian.

          -  Known or suspected intolerance or hypersensitivity to the study materials (or closely
             related compounds) or any of their stated ingredients.

          -  Indication that child is likely to move out of geographical range of the study within
             the period of study intervention and activities, thus hindering the child's compliance
             to study activities.

          -  Clinical Study/Experimental Medication: a) Participation in another clinical study or
             receipt of an investigational drug within 30 days of the screening visit,
             participation in any nutritional study or didactic nutrition education in the last 6
             months of the screening visit and previous participation in this study.

          -  Child with severe anaemia (Hemoglobin &lt;8g/dL).

          -  Children with history of use of immunosuppressive therapy e.g. oral corticosteroids or
             chemotherapy in past six months prior to the screening visit.

          -  Current or relevant history of any serious, severe or unstable physical or psychiatric
             illness or any medical disorder that would make the participant unlikely to fully
             complete the study or any condition that presents undue risk from the test product or
             procedures, on the discretion of study physician.

          -  Recent history [2 months] of serious infections, injuries and/ or surgeries in the
             opinion of the investigator.

          -  Children consuming nutritional supplements and/or health food drinks on a regular
             basis (≥3 times a week) in last 3 months.

          -  Child belonging to an employee of the sponsor or the study site or members of their
             immediate family or sibling of a child already enrolled in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pune</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2015</study_first_submitted>
  <study_first_submitted_qc>September 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2015</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

